Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.